Efficacy and safety of sunitinib in the management of metastatic kidney cancer according to overall survival

Authors

  • Paredes Barzola
  • Unda Vernelle
  • Barragán Camacho
  • Rivas Manrique
  • Martínez Castillo
  • Estrada Guevara
  • Espinoza Hidalgo
  • Almira Gonzales
  • Lozano Rodríguez
  • Loor Galarza
  • León Rodríguez

Keywords:

Kidney Cancer, Sunitinib, metástasis

Abstract

Sunitinib, a tyrosinkinase inhibitor, is among the first-line recommendations for the treatment of metastatic kidney cancer. The objective of the present study was to describe the benefit of sunitinib on survival and the main adverse effects in patients treated at the Teodoro Maldonado Carbo Hospital.

Downloads

Download data is not yet available.
Portada Revista Científica Ciencia y Avance Vólumen 1 Número 1

Downloads

Published

2022-04-05

How to Cite

1.
Barzola P, Vernelle U, Camacho B, Manrique R, Castillo M, Guevara E, Hidalgo E, Gonzales A, Rodríguez L, Galarza L, Rodríguez L. Efficacy and safety of sunitinib in the management of metastatic kidney cancer according to overall survival. REVISTA CYA [Internet]. 2022 Apr. 5 [cited 2024 Nov. 22];1(1). Available from: https://revista.htmc.gob.ec/ojs-3.3.0-10/index.php/hetmc/article/view/12

Issue

Vol. 1 No. 1 (2022): April 2022

Section

ORIGINAL ARTICLE

License

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

The authors retain the rights to the articles and are therefore free to share, copy, distribute, perform and publicly communicate the work on their personal websites or in institutional repositories, after publication in this journal, as long as they provide information bibliography that certifies its publication in this journal.

Licencia Creative Commons

The works are under one

 https://creativecommons.org/licenses/by-nc-nd/4.0/